Drugs / AAV1-gamma-sarcoglycan vector
AAV1-gamma-sarcoglycan vector
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01344798 | Nov 2006 → Jun 2010 | autosomal recessive limb-girdle muscular dystrophy type 2C | Genethon | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAV1-gamma-sarcoglycan vector | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01344798 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “AAV1-gamma-sarcoglycan Gene Therapy” NCT01344798 ↗ |
| Route | Intramuscular | “single intramuscular injection into carpi radialis muscle under open procedure” NCT01344798 ↗ |